These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 10665632)
1. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632 [TBL] [Abstract][Full Text] [Related]
2. The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis. Romeo R; Knapp M; Tyrer P; Crawford M; Oliver-Africano P J Intellect Disabil Res; 2009 Jul; 53(7):633-43. PubMed ID: 19460067 [TBL] [Abstract][Full Text] [Related]
4. Olanzapine: an updated review of its use in the management of schizophrenia. Bhana N; Foster RH; Olney R; Plosker GL Drugs; 2001; 61(1):111-61. PubMed ID: 11217867 [TBL] [Abstract][Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
6. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor DM; Wright T; Libretto SE; J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664 [TBL] [Abstract][Full Text] [Related]
7. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983 [TBL] [Abstract][Full Text] [Related]
8. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. Bounthavong M; Okamoto MP J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814 [TBL] [Abstract][Full Text] [Related]
9. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335 [TBL] [Abstract][Full Text] [Related]
10. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [TBL] [Abstract][Full Text] [Related]
11. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775 [TBL] [Abstract][Full Text] [Related]
12. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Chouinard G; Albright PS J Clin Psychopharmacol; 1997 Aug; 17(4):298-307. PubMed ID: 9241010 [TBL] [Abstract][Full Text] [Related]
13. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Carter CS; Mulsant BH; Sweet RA; Maxwell RA; Coley K; Ganguli R; Branch R Psychopharmacol Bull; 1995; 31(4):719-25. PubMed ID: 8851645 [TBL] [Abstract][Full Text] [Related]
14. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
15. Risperidone in treatment-refractory schizophrenia. Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947 [TBL] [Abstract][Full Text] [Related]
16. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Bobes J; Cañas F; Rejas J; Mackell J Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1287-97. PubMed ID: 15588755 [TBL] [Abstract][Full Text] [Related]
17. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740 [TBL] [Abstract][Full Text] [Related]
18. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL Value Health; 2004; 7(1):22-35. PubMed ID: 14720128 [TBL] [Abstract][Full Text] [Related]
19. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Heck AH; Haffmans PM; de Groot IW; Hoencamp E Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421 [TBL] [Abstract][Full Text] [Related]
20. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis. Lucey JV; Libretto SE Ir J Med Sci; 2003; 172(4):195-201. PubMed ID: 15029989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]